Patent ID: 7202213

Claim:
A pharmaceutical composition comprising a glucagon like peptide-1 (GLP-1) derivative and a dual Peroxisome Proliferator-Activated Receptor-α/Peroxisome Proliferator Activated Receptor-γ (PPARα/PPAR-γ) activator wherein the dual PPAR-α/PPAR-γ activator is a compound of formula (I) wherein X is hydrogen or X is C 1-2 -alkyl, C 2-12 -alkenyl, C 2-12 -alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl or heterocyclyl each of which is optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, hydroxy, C 1-6 -alkoxy, C 1-6 -alkylthio, aryl, aryloxy, arylthio, acyl, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, C 1-6 -alkylthio, cyano, amino, C 1-6 -alkylamino, C 1-6 -dialkylamino, carboxy or C 1-6 -alkylester; and Y is hydrogen or Y is C 1-12 -alkyl, C 2-12 -alkenyl, C 2-12 -alkynyl, C 4-12 -alkenynyl, aryl, heteroaryl, aralkyl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, C 1-6 alkyl, perhalomethyl, hydroxy, aryl, heteroaryl, amino, carboxy or C 1-6 alkylester; and Z is hydrogen, halogen, hydroxy or Z is C 1-6 alkyl or C 1-6 alkoxy each of which is optionally substituted with one or more substituents selected from C 1-6 -alkoxy, halogen, hydroxy, carboxy, amino or cyano; and Q is O, S or NR 5 , wherein R 5 is hydrogen, C 1-6 alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 4-6 -alkenynyl, aralkyl or heteroaralkyl and wherein R 5 is optionally substituted with one or more substituents selected from halogen, hydroxy, C 1-6 -alkoxy, amino or carboxy; and Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C 1-6 alkyl, aryl or C 1-6 -alkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy or C 1-6 -alkylester; and R 1 is hydrogen, hydroxy or halogen; or R 1 forms a bond together with R 2 ; and R 2 is hydrogen or C 1-6 -alkyl; or R 2 forms a bond together with R 1 ; and R 3 is hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 4-6 -alkenynyl, aryl, aralkyl, C 1-6 -alkoxyC 1-6 -alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy, cyano, carboxy or C 1-6 -alkylester; and R 4 is hydrogen, C 1-6 alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 4-6 -alkenynyl or aryl; n is an integer ranging from 0 to 3; and m is an integer ranging from 0 to 1; or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers, racemic mixture, or polymorphs.